Early data from trials assessing the new Pfizer and BioNTech omicron-adapted booster vaccine show that the vaccine substantially increased protective antibodies against the BA.5 subvariant in adults.
“While we expect more mature immune response data from the clinical trial of our omicron BA.4/BA.5-adapted bivalent vaccine in the coming weeks, we are pleased to see encouraging responses just 1 week after vaccination in younger and older adults,” Pfizer chairman and CEO Albert Bourla, DVM, PhD, said in a press release. “These early data suggest that our bivalent vaccine is